Caxton Associates LP Sells 3,505 Shares of Zoetis Inc (ZTS)

Caxton Associates LP decreased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 43.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,606 shares of the company’s stock after selling 3,505 shares during the quarter. Caxton Associates LP’s holdings in Zoetis were worth $394,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. raised its holdings in Zoetis by 3.2% during the fourth quarter. Whittier Trust Co. now owns 4,039 shares of the company’s stock worth $345,000 after purchasing an additional 124 shares in the last quarter. North Star Investment Management Corp. raised its holdings in Zoetis by 0.6% during the fourth quarter. North Star Investment Management Corp. now owns 22,525 shares of the company’s stock worth $1,927,000 after purchasing an additional 125 shares in the last quarter. Sandy Spring Bank raised its holdings in Zoetis by 0.4% during the fourth quarter. Sandy Spring Bank now owns 29,716 shares of the company’s stock worth $2,542,000 after purchasing an additional 125 shares in the last quarter. InterOcean Capital LLC raised its holdings in Zoetis by 5.0% during the fourth quarter. InterOcean Capital LLC now owns 2,945 shares of the company’s stock worth $252,000 after purchasing an additional 139 shares in the last quarter. Finally, Harvest Management LLC raised its holdings in Zoetis by 8.0% during the fourth quarter. Harvest Management LLC now owns 2,700 shares of the company’s stock worth $231,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 89.98% of the company’s stock.

Several research analysts recently issued reports on the stock. Stifel Nicolaus raised shares of Zoetis from a “hold” rating to a “buy” rating and increased their price target for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a report on Saturday, February 16th. BMO Capital Markets increased their price target on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a report on Monday, February 25th. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus target price of $98.85.

In other news, insider Heidi C. Chen sold 15,710 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $95.49, for a total value of $1,500,147.90. Following the sale, the insider now directly owns 13,963 shares in the company, valued at $1,333,326.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Clinton A. Jr. Lewis sold 6,125 shares of the stock in a transaction that occurred on Monday, January 14th. The shares were sold at an average price of $85.21, for a total transaction of $521,911.25. Following the completion of the sale, the insider now owns 48,070 shares in the company, valued at $4,096,044.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 406,209 shares of company stock valued at $38,120,373. 0.35% of the stock is currently owned by corporate insiders.

Shares of Zoetis stock opened at $96.91 on Friday. Zoetis Inc has a 12-month low of $77.00 and a 12-month high of $97.95. The company has a debt-to-equity ratio of 2.95, a current ratio of 3.60 and a quick ratio of 2.46. The stock has a market capitalization of $46.40 billion, a price-to-earnings ratio of 30.96, a P/E/G ratio of 1.74 and a beta of 0.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The company had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period last year, the company posted $0.69 earnings per share. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc will post 3.46 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be issued a $0.164 dividend. The ex-dividend date of this dividend is Wednesday, April 17th. This represents a $0.66 dividend on an annualized basis and a yield of 0.68%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

Zoetis announced that its board has approved a stock repurchase plan on Wednesday, December 12th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2019/03/17/caxton-associates-lp-sells-3505-shares-of-zoetis-inc-zts.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.